JP2018538343A5 - - Google Patents

Download PDF

Info

Publication number
JP2018538343A5
JP2018538343A5 JP2018532777A JP2018532777A JP2018538343A5 JP 2018538343 A5 JP2018538343 A5 JP 2018538343A5 JP 2018532777 A JP2018532777 A JP 2018532777A JP 2018532777 A JP2018532777 A JP 2018532777A JP 2018538343 A5 JP2018538343 A5 JP 2018538343A5
Authority
JP
Japan
Prior art keywords
red blood
cells
composition
cell
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018532777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018538343A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2016/000404 external-priority patent/WO2017106899A2/en
Publication of JP2018538343A publication Critical patent/JP2018538343A/ja
Publication of JP2018538343A5 publication Critical patent/JP2018538343A5/ja
Priority to JP2021109883A priority Critical patent/JP2021155454A/ja
Pending legal-status Critical Current

Links

JP2018532777A 2015-12-22 2016-12-22 赤血球を用いる治療方法 Pending JP2018538343A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021109883A JP2021155454A (ja) 2015-12-22 2021-07-01 赤血球を用いる治療方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015905309A AU2015905309A0 (en) 2015-12-22 Therapeutic methods using erythrocytes
AU2015905309 2015-12-22
PCT/AU2016/000404 WO2017106899A2 (en) 2015-12-22 2016-12-22 Therapeutic methods using erythrocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021109883A Division JP2021155454A (ja) 2015-12-22 2021-07-01 赤血球を用いる治療方法

Publications (2)

Publication Number Publication Date
JP2018538343A JP2018538343A (ja) 2018-12-27
JP2018538343A5 true JP2018538343A5 (https=) 2020-02-06

Family

ID=59088638

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018532777A Pending JP2018538343A (ja) 2015-12-22 2016-12-22 赤血球を用いる治療方法
JP2021109883A Pending JP2021155454A (ja) 2015-12-22 2021-07-01 赤血球を用いる治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021109883A Pending JP2021155454A (ja) 2015-12-22 2021-07-01 赤血球を用いる治療方法

Country Status (9)

Country Link
US (1) US11564948B2 (https=)
EP (1) EP3393482A4 (https=)
JP (2) JP2018538343A (https=)
KR (1) KR20180102096A (https=)
CN (1) CN108883133A (https=)
AU (1) AU2016374643B2 (https=)
CA (1) CA3009369A1 (https=)
SG (1) SG11201805052YA (https=)
WO (1) WO2017106899A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107058101B (zh) 2011-10-17 2021-06-01 麻省理工学院 细胞内传递
EP3033184B1 (en) 2013-08-16 2021-03-31 Massachusetts Institute of Technology Selective delivery of material to cells
JP7523203B2 (ja) 2014-10-31 2024-07-26 マサチューセッツ インスティテュート オブ テクノロジー 生体分子の免疫細胞への送達
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
CN107250373A (zh) 2015-01-12 2017-10-13 麻省理工学院 通过微流体递送实现的基因编辑
SG10201912910PA (en) 2015-07-09 2020-02-27 Massachusetts Inst Technology Delivery of materials to anucleate cells
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
JP6824994B2 (ja) 2015-10-07 2021-02-03 サングイ バイオ ピーティーワイ． エルティーディー 血液の調製及びプロファイリング
AU2017379367B2 (en) * 2016-12-20 2023-12-07 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors
WO2022192429A1 (en) * 2021-03-10 2022-09-15 Terasaki Insutitute For Biomedical Innovation Constructs comprising fibrin or other blood products for meat cultivation and other applications

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931276A (en) 1987-10-30 1990-06-05 Franco Robert S Method for introducing desired agents into red blood cells
US5858358A (en) * 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
AU8869291A (en) * 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
FR2778851B1 (fr) * 1998-05-19 2002-07-26 Aetsrn Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes
US8431117B2 (en) * 1999-08-30 2013-04-30 David S Terman Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects
AU2001272670A1 (en) * 2000-07-24 2002-02-05 Gendel Limited Polypeptide delivery II-2
ES2498369T3 (es) 2002-04-16 2014-09-24 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Un marcador para medir cirrosis hepática
GB0325483D0 (en) 2003-10-31 2003-12-03 Plasmacute As Assay
US20080095749A1 (en) * 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
US7378054B2 (en) 2004-04-16 2008-05-27 Savvipharm Inc Specimen collecting, processing and analytical assembly
US20060166223A1 (en) 2005-01-26 2006-07-27 Reed Michael W DNA purification and analysis on nanoengineered surfaces
US20090054741A1 (en) 2005-03-29 2009-02-26 Inverness Medical Switzerland Gmbh Device and method of monitoring a patient
WO2008134526A2 (en) 2007-04-27 2008-11-06 University Of Florida Research Foundation Inc. Glycoprotein profiling of bladder cancer
FR2919804B1 (fr) * 2007-08-08 2010-08-27 Erytech Pharma Composition et vaccin therapeutique anti-tumoral
US20110245092A1 (en) 2008-03-04 2011-10-06 John Bilello Diagnosing and monitoring depression disorders based on multiple serum biomarker panels
JP5748654B2 (ja) 2008-05-06 2015-07-15 オカタ セラピューティクス， インコーポレイテッド 多能性幹細胞に由来する除核赤血球細胞を産生するための方法
WO2010147621A1 (en) 2009-06-16 2010-12-23 The Trustees Of Columbia University In The City Of New York Methods for ameliorating adverse effects associated with transfusion of aged red blood cells
CN102472744B (zh) 2009-08-13 2015-11-25 巴斯夫欧洲公司 诊断甲状腺疾病的手段和方法
US20130202625A1 (en) * 2010-01-21 2013-08-08 The Regents Of The University Of Californa Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
WO2011127056A2 (en) 2010-04-05 2011-10-13 The Uab Research Foundation Biomarkers for assessing exposure to ionizing radiation and absorbed dose
SG195180A1 (en) 2011-05-31 2013-12-30 Singapore Health Serv Pte Ltd Method for detecting disease biomarkers
BR112013032659B1 (pt) * 2011-07-06 2021-04-06 Histocell S.L. Método para o tratamento de células-tronco mesenquimais, que compreende a obtenção e o isolamento das células-tronco mesenquimais e a cultura das células em um meio de tratamento; e uso das células
GB201116767D0 (en) * 2011-09-28 2011-11-09 St George S Hospital Medical School Treatment for mitrochondrial neurogastrointestinal encephalomyopathy
HK1204578A1 (en) * 2012-03-21 2015-11-27 Erytech Pharma Medicament for the treatment of acute myeloid leukemia (aml)
HU230341B1 (hu) 2012-04-20 2016-02-29 Advancell Diagnosztika Kft. A vörösvérsejt-membrán kvantitatív biomarkerei
WO2014011901A2 (en) 2012-07-11 2014-01-16 Sangamo Biosciences, Inc. Methods and compositions for delivery of biologics
US10272115B2 (en) * 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
EP4338803A3 (en) * 2013-05-10 2024-10-09 Quince Therapeutics S.p.A. Process for the preparation of erythrocytes loaded with one or more substances of pharmaceutical interest and so obtained erythrocytes
JP6383920B2 (ja) 2013-09-11 2018-09-05 有限会社ピコデバイス パーキンソン病の判定基準とする方法
EP3130668B1 (en) * 2014-04-07 2019-07-17 IUCF-HYU (Industry-University Cooperation Foundation Hanyang University) In-vitro expansion of erythroid cells
IL289099B2 (en) 2015-05-18 2024-04-01 Hemanext Inc Methods for the storage of whole blood, and compositions thereof
JP6824994B2 (ja) 2015-10-07 2021-02-03 サングイ バイオ ピーティーワイ． エルティーディー 血液の調製及びプロファイリング
AU2017379367B2 (en) 2016-12-20 2023-12-07 Sangui Bio Pty. Ltd Blood profiling with protease inhibitors

Similar Documents

Publication Publication Date Title
JP2018538343A5 (https=)
Gangaplara et al. Type I interferon signaling attenuates regulatory T cell function in viral infection and in the tumor microenvironment
Yates et al. Multipotent stromal cells/mesenchymal stem cells and fibroblasts combine to minimize skin hypertrophic scarring
Lambe et al. DOCK8 is essential for T‐cell survival and the maintenance of CD8+ T‐cell memory
Strutt et al. Multipronged CD 4+ T‐cell effector and memory responses cooperate to provide potent immunity against respiratory virus
Aparicio‐Domingo et al. Fibroblast‐derived IL‐33 is dispensable for lymph node homeostasis but critical for CD8 T‐cell responses to acute and chronic viral infection
CA3059634A1 (en) Combinatorial cancer immunotherapy
US20150258143A1 (en) Method of providing cellular therapy using modified natural killer cells or t lymphocytes
JP2017500061A5 (https=)
Mathä et al. Migration of lung resident group 2 innate lymphoid cells link allergic lung inflammation and liver immunity
Verbist et al. A role for IL-15 in the migration of effector CD8 T cells to the lung airways following influenza infection
Feng et al. Ex vivo induced regulatory T cells regulate inflammatory response of Kupffer cells by TGF-beta and attenuate liver ischemia reperfusion injury
Wang et al. Current therapeutic strategies for respiratory diseases using mesenchymal stem cells
Yao et al. Downregulation of T-bet/GATA-3 ratio induced by IL-11 treatment is responsible for Th1/Th2 balance restoration in human immune thrombocytopenic purpura (ITP)
Liu et al. Over-expression of CXCR4 on mesenchymal stem cells protect against experimental colitis via immunomodulatory functions in impaired tissue
Moffat et al. Granzyme A expression reveals distinct cytolytic CTL subsets following influenza A virus infection
Zheng et al. Phenotypic and functional characteristics of a novel influenza virus hemagglutinin-specific memory NK cell
Cantoni et al. Role of NK cells in immunotherapy and virotherapy of solid tumors
Sun et al. NLRC5 deficiency has a moderate impact on immunodominant CD 8+ T‐cell responses during rotavirus infection of adult mice
Zhou et al. Protective effect of trichostatin A on CD19+ CD5+ CD1d high regulatory B cells in heart transplantation
Lam et al. Targeting mesenchymal stem cell therapy for severe pneumonia patients
EP4412712A1 (en) Il-2 prodrug
US20200281976A1 (en) Prevention and treatment of gvhd and autoimmune diseases
Sturm et al. Functional hyper-IL-6 from vaccinia virus-colonized tumors triggers platelet formation and helps to alleviate toxicity of mitomycin C enhanced virus therapy
Yomogida et al. Cell penetrating recombinant Foxp3 protein enhances Treg function and ameliorates arthritis